Triple immunofluorescence staining for prediction of relapse in childhood precursor B acute lymphoblastic leukaemia

Area of Science:

• Hematology
• Immunology
• Pediatric Oncology

Background:

• Precursor B acute lymphoblastic leukemia (B-ALL) is a common childhood cancer.
• Identifying rare cell phenotypes in bone marrow is crucial for monitoring treatment response and predicting relapse.
• Current methods may lack the sensitivity or speed for early relapse detection.

Purpose of the Study:

• To develop and validate a fast, sensitive three-color immunofluorescence assay for detecting rare cell phenotypes in pediatric B-ALL.
• To assess the utility of this assay in predicting relapse within the first year of therapy.
• To differentiate between malignant and normal precursor B cells using immunofluorescence.

Main Methods:

• Utilized three-color immunofluorescence for cell detection.
• Analyzed bone marrow samples from children with B-ALL (diagnosed and relapsed).
• Quantified specific cell populations (CD10+ CD19+, CD20- CD22+) within the CD34+ cell gate.
• Compared immunofluorescence data with Polymerase Chain Reaction (PCR) results.

Main Results:

• The percentage of CD10+ CD19+ and CD20- CD22+ cells in the CD34+ population indicated relapse likelihood in 17/18 patients within the first year of therapy.
• Suppression of these phenotypes followed by normal precursor B cell outgrowth occurred after 12 months.
• Only a subpopulation of identified cells, above a determined threshold, represented malignant cells when compared to PCR.
• The predictive value was limited to the first year post-chemotherapy initiation.

Conclusions:

• Three-color immunofluorescence offers a rapid and sensitive method for early relapse detection in pediatric B-ALL.
• The assay's predictive value is highest within the first year of treatment.
• Further prospective studies are needed to confirm the assay's clinical utility and refine the identification of malignant cells.